

# Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

NCT04993885

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Institute of Hematology & Blood Diseases Hospital, China
<b>Enrollment</b>	52 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- The patients have provided written informed consent prior to enrollment.
- Men and women greater than or equal to 18 years of age.
- Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.
- Platelet count  $< 30 \times 10^9/L$  at screening.
- Patients who have previously failed to receive Eltrombopag or Herombopag [poor efficacy (Eltrombopag 75 mg/d or Herombopag 7.5 mg/D, at least 4 weeks), or the efficacy cannot be maintained], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment.

... and 2 more (see full listing online)

### Exclusion (19)

- Patients with active thyroid disease requiring treatment.
- Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.
- Those who had received rituximab within 3 months.
- Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks).
- Subjects known to be allergic to Avatrombopag or any of its excipients.

... and 14 more (see full listing online)

## Locations (1 total)

---

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China